Can beta-lactams be re-engineered to beat MRSA?

@article{Livermore2006CanBB,
  title={Can beta-lactams be re-engineered to beat MRSA?},
  author={David Martin Livermore},
  journal={Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
  year={2006},
  volume={12 Suppl 2},
  pages={
          11-6
        }
}
Methicillin-resistant Staphylococcus aureus (MRSA) strains are important nosocomial pathogens worldwide and now are also of growing importance in community-acquired infection. Their resistance depends upon a supplementary peptidoglycan transpeptidase, PBP2' (PBP-2a), which continues to function when normal PBPs have been inactivated by beta-lactams. PBP2' is encoded by the mecA gene, which is carried by the staphylococcal cassette chromosome, a large and somewhat variable DNA insert of… CONTINUE READING
Highly Cited
This paper has 32 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Optimizing therapy for MRSA pneumonia.

Seminars in respiratory and critical care medicine • 2007
View 7 Excerpts
Highly Influenced

Appropriate Targets for Antibacterial Drugs.

Cold Spring Harbor perspectives in medicine • 2016
View 2 Excerpts

A new antibiotic: lessons and perspectives.

International journal of clinical practice • 2008